Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Allogenic Adipose-derived Mesenchymal Stromal Cells for Mouth Fibrosis in Systemic Sclerosis
2024-518516-39-00Phase 2Authorised
- Sponsor
- Centre hospitalier universitaire de Toulouse
- Start
- Oct 2026
- Modality
- Stem Cell Therapies → Cell Therapies
- Countries
- 1
01
Overview
Phase 2 trial of CellReady in systemic sclerosis (SSc), sponsored by Centre hospitalier universitaire de Toulouse. Primary endpoint: Change in Mouth Handicap in Systemic Sclerosis Scale (MHISS). Planned start Oct 2026; status: authorised.
02
Drugs
CellReady
03
Conditions
systemic sclerosis (SSc)
Beyond the preview
Go deeper on 2024-518516-39-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-518516-39-00.